InsiderTrades

Form 4 for AMGN Amgen

Accepted 2023-05-02 00:00:00 ET · period of report 2023-04-30 · accession 0001127602-23-014153 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
2023-05-02 2023-04-30 AMGN Grygiel Nancy A. SVP, CCO F - Tax $239.74 -73 13.7K -0.5% -$17.5K

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2023-04-30 F D 73 $239.74 13,705 D — — (F1) These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plan: 154 RSUs which vest in one installment on 5/3/2023; 284 RSUs which vest in installments of 140 on 5/5/2023 and 144 on 5/5/2024; 5,477 RSUs which will vest in installments of 2,697 on 7/31/2023 and 2,780 on 7/31/2024; 392 RSUs which vest in installments of 193 on 4/30/2024 and 199 on 4/30/2025; 468 RSUs which will vest on 11/5/2023; and 649 RSUs which will vest in two installments of 214 on 5/2/2024 and 5/2/2025, and one installment of 221 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. (F2) These shares include 604 DEs granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.